Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.

Frontiers in immunology - 1 Jan 2022

Wang Deqiang, Chen Xiaofeng, Du Yian, Li Xiaoqin, Ying Leqian, Lu Yi, Shen Bo, Gao Xuan, Yi Xin, Xia Xuefeng, Sui Xinbing, Shu Yongqian

Abstract excerpt

Background: HER2 is one of the most extensively studied oncogenes in solid tumors. However, the association between tumor microenvironment (TME) and HER2 mutation remains elusive, and there are no specific therapies for HER2-mutated tumors. Immune checkpoint inhibitors (ICIs) have been approved for some tumor subgroups that lack targeted therapies, while their effects are still unclear in HER2-mutated tumors. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Receptor, ErbB-2

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35281032
DOI: 10.3389/fimmu.2022.799988
PMCID: PMC8905508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.PMID 35281032Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis.Semantic proximity Read ↗

Novel Immune Subtypes Identification of HER2 Positive Breast Cancer Based On Immunogenomic LandscapeSemantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.Semantic proximity Read ↗

Integrated analysis of LRP2 mutation to immunotherapy efficacy in pan-cancer cohortSemantic proximity Read ↗

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancerSemantic proximity Read ↗

Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancersSemantic proximity Read ↗

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.Semantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity Read ↗

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.